|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: Cancer incidence and mortality worldwide sources, methods
and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–86.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van Rhijn BW, Burger M, Lotan Y, Solsona
E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and
progression of disease in non-muscle-invasive bladder cancer: From
epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Drayton RM and Catto JW: Molecular
mechanisms of cisplatin resistance in bladder cancer. Expert Rev
Anticancer Ther. 12:271–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fang Y and Fullwood MJ: Roles, functions,
and mechanisms of long non-coding RNAs in cancer. Genomics
Proteomics Bioinformatics. 14:42–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jacobs BL, Lee CT and Montie JE: Bladder
cancer in 2010: How far have we come? CA Cancer J Clin. 60:244–272.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gibb EA, Brown CJ and Lam WL: The
functional role of long non-coding RNA in human carcinomas. Mol
Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Olivieri M, Ferro M, Terreri S, Durso M,
Romanelli A, Avitabile C, De Cobelli O, Messere A, Bruzzese D,
Vannini I, et al: Long non-coding RNA containing ultraconserved
genomic region 8 promotes bladder cancer tumorigenesis. Oncotarget.
7:20636–20654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao F, Lin T, He W, Han J, Zhu D, Hu K,
Li W, Zheng Z, Huang J and Xie W: Knockdown of a novel lincRNA
AATBC suppresses proliferation and induces apoptosis in bladder
cancer. Oncotarget. 6:1064–1078. 2015.PubMed/NCBI
|
|
9
|
Zhu H, Li X, Song Y, Zhang P, Xiao Y and
Xing Y: Long non-coding RNA ANRIL is up-regulated in bladder cancer
and regulates bladder cancer cell proliferation and apoptosis
through the intrinsic pathway. Biochem Biophys Res Commun.
467:223–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He A, Liu Y, Chen Z, Li J, Chen M, Liu L,
Liao X, Lv Z, Zhan Y, Zhuang C, et al: Over-expression of long
noncoding RNA BANCR inhibits malignant phenotypes of human bladder
cancer. J Exp Clin Cancer Res. 35:1252016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taft RJ, Pang KC, Mercer TR, Dinger M and
Mattick JS: Non-coding RNAs: Regulators of disease. J Pathol.
220:126–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang ZL, Li B, Piccolo SR, Zhang XQ, Li
JH, Zhou H, Yang JH and Qu LH: Integrative analysis reveals
clinical phenotypes and oncogenic potentials of long non-coding
RNAs across 15 cancer types. Oncotarget. 7:35044–35055.
2016.PubMed/NCBI
|
|
13
|
Kong YG, Cui M, Chen SM, Xu Y, Xu Y and
Tao ZZ: LncRNA-LINC00460 facilitates nasopharyngeal carcinoma
tumorigenesis through sponging miR-149-5p to up-regulate IL6. Gene.
639:77–84. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao W, Liu JN, Liu Z, Wang X, Han ZG, Ji
T, Chen WT and Zou X: A three-lncRNA signature derived from the
Atlas of ncRNA in cancer (TANRIC) database predicts the survival of
patients with head and neck squamous cell carcinoma. Oral Oncol.
65:94–101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Tao Y and Liao Q: Long noncoding
RNA: A crosslink in biological regulatory network. Brief Bioinform.
19:930–945. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 65:7–30. 2016. View Article : Google Scholar
|
|
17
|
Hartge P, Harvey EB, Linehan WM, Silverman
DT, Sullivan JW, Hoover RN and Fraumeni JF Jr: Unexplained excess
risk of bladder cancer in men. J Natl Cancer Inst. 82:1636–1640.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hemelt M, Yamamoto H, Cheng KK and Zeegers
MP: The effect of smoking on the male excess of bladder cancer: A
meta-analysis and geographicalanalyses. Int J Cancer. 124:412–419.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Overdevest JB, Knubel KH, Duex JE, Thomas
S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M and
Theodorescu D: CD24 expression is important in male urothelial
tumorigenesis and metastasis in mice and is androgen regulated.
Proc Natl Acad Sci USA. 109:E3588–E3596. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawahara T, Shareef HK, Aljarah AK, Ide H,
Li Y, Kashiwagi E, Netto GJ, Zheng Y and Miyamoto H: ELK1 is
up-regulated by androgen in bladder cancer cells and promotes tumor
progression. Oncotarget. 6:29860–29876. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ding G, Yu S, Cheng S, Li G and Yu Y:
Androgen receptor (AR) promotes male bladder cancer cell
proliferation and migration via regulating CD24 and VEGF. Am J
Transl Res. 8:578–587. 2016.PubMed/NCBI
|
|
22
|
Robinson MD, McCarthy DJ and Smyth GK:
edgeR: A Bioconductor package for differential expression analysis
of digital gene expression data. Bioinformatics. 26:139–140. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Papatheodorou I, Fonseca NA, Keays M, Tang
YA, Barrera E, Bazant W, Burke M, Füllgrabe A, Fuentes AM, George
N, et al: Expression Atlas: Gene and protein expression across
multiple studies and organisms. Nucleic Acids Res. 46(D1):
D246–D251. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pasin E, Josephson DY, Mitra AP, Cote RJ
and Stein JP: Superficial bladder cancer: An update on etiology,
molecular development, classification, and natural history. Rev
Urol. 10:31–43. 2008.PubMed/NCBI
|
|
26
|
Stein JP, Lieskovsky G, Cote R, Groshen S,
Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M,
et al: Radical cystectomy in the treatment of invasive bladder
cancer: Long-term results in 1,054 patients. J Clin Oncol.
19:666–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER cancer statistics review, 1975–2012. Natl Cancer Inst.
2015.
|
|
28
|
Sternberg CN, de Mulder P, Schornagel JH,
Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van
Groeningen CJ, Duclos B, et al: Seven year update of an EORTC phase
III trial of high-dose intensity M-VAC chemotherapy and G-CSF
versus classic M-VAC in advanced urothelial tract tumours. Eur J
Cancer. 42:50–54. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saxman SB, Propert KJ, Einhorn LH,
Crawford ED, Tannock I, Raghavan D, Loehrer PJ Sr and Trump D:
Long-term follow-up of a phase III intergroup study of cisplatin
alone or in combination with methotrexate, vinblastine, and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol. 15:2564–2569. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Berrondo C, Flax J, Kucherov V, Siebert A,
Osinski T, Rosenberg A, Fucile C, Richheimer S and Beckham CJ:
Expression of the long non-coding RNA HOTAIR Correlates with
disease progression in bladder cancer and is contained in bladder
cancer patient urinary exosomes. PLoS One. 11:e01472362016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F
and Liu Y: TGF-β-induced upregulation of malat1 promotes bladder
cancer metastasis by associating with suz12. Clin Cancer Res.
20:1531–1541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xue M, Pang H, Li X, Li H, Pan J and Chen
W: Long non-coding RNA urothelial cancer-associated 1 promotes
bladder cancer cell migration and invasion by way of the
hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer Sci. 107:18–27. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li JR, Sun CH, Li W, Chao RF, Huang CC,
Zhou XJ and Liu CC: Cancer RNA-Seq Nexus: A database of
phenotype-specific transcriptome profiling in cancer cells. Nucleic
Acids Res. 44:D944–D951. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Atienza JM, Roth RB, Rosette C, Smylie KJ,
Kammerer S, Rehbock J, Ekblom J and Denissenko MF: Suppression of
RAD21 gene expression decreases cell growth and enhances
cytotoxicity of etoposide and bleomycin in human breast cancer
cells. Mol Cancer Ther. 4:361–368. 2005.PubMed/NCBI
|
|
36
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B,
Li F and Miyamoto H: Androgen activates β-catenin signaling in
bladder cancer cells. Endocr Relat Cancer. 20:293–304. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shiota M, Takeuchi A, Yokomizo A,
Kashiwagi E, Tatsugami K, Kuroiwa K and Naito S: Androgen receptor
signaling regulates cell growth and vulnerability to doxorubicin in
bladder cancer. J Urol. 188:276–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu JT, Han BM, Yu SQ, Wang HP and Xia SJ:
Androgen receptor is a potential therapeutic target for bladder
cancer. Urology. 75:820–827. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng Y, Izumi K, Yao JL and Miyamoto H:
Dihydrotestosterone upregulates the expression of epidermal growth
factor receptor and ERBB2 in androgen receptor-positive bladder
cancer cells. Endocr Relat Cancer. 18:451–464. 2011. View Article : Google Scholar : PubMed/NCBI
|
